A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425.

被引：2
|
作者：
Yamada, Kazuhiko
Miyamoto, Shingo
Azuma, Koichi
Ishii, Hidenobu
Bessho, Akihiro
Fukamatsu, Nobuaki
Kunitoh, Hideo
Ishii, Mari
Tanaka, Hiroshi
Aono, Hiromi
Nakahara, Yoshiro
Kusaka, Kei
Hosomi, Yukio
Kikuchi, Norihiro
Mori, Yoshiaki
Itani, Hidetoshi
Kasai, Takashi
Ichiki, Masao
Seki, Nobuhiko
Okamoto, Hiroaki
机构：
[1] Kurume Univ, Sch Med, Div Respirol Neurol & Rheumatol, Dept Internal Med, Kurume, Fukuoka, Japan
[2] Japanese Red Cross Med Ctr, Tokyo, Japan
[3] Japanese Red Cross Okayama Hosp, Okayama, Japan
[4] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan
[5] Niigata Canc Ctr Hosp, Dept Resp Med, Niigata, Japan
[6] Mitsui Mem Hosp, Tokyo, Japan
[7] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[8] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan
[9] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[10] Kasumigaura Med Ctr, Tsuchiura, Ibaraki, Japan
[11] Iwate Cent Prefectural Hosp, Morioka, Iwate, Japan
[12] Japanese Red Cross Ise Hosp, Ise, Japan
[13] Tochigi Canc Ctr, Dept Resp Med, Utsunomiya, Tochigi, Japan
[14] Kyushu Med Ctr, Fukuoka, Fukuoka, Japan
[15] Teikyo Univ, Sch Med, Tokyo, Japan
[16] Yokohama Municipal Citizens Hosp, Dept Resp Med & Med Oncol, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9063
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I/II trial of erlotinib S-1 therapy in patients with non-small cell lung carcinoma: Thoracic Oncology Reseach Group (TORG) 0808/0913.
    Nogami, Naoyuki
    Shinkai, Tetsu
    Kozuki, Toshiyuki
    Ogino, Atsuko
    Kato, Yuka
    Hosomi, Yukio
    Hida, Naoya
    Shimokawa, Tsuneo
    Seki, Nobuhiko
    Okamoto, Hiroaki
    Shibuya, Masahiko
    Watanabe, Koshiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
    Fujimoto, D.
    Yokoyama, T.
    Yoshioka, H.
    Demura, Y.
    Hirano, K.
    Kawai, T.
    Kagami, R.
    Ishida, T.
    Tomii, K.
    Akai, M.
    Hirabayashi, M.
    Nishimura, T.
    Nakahara, Y.
    Kim, Y. H.
    Yoshimura, K.
    Hirai, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] A PHASE I/II TRIAL OF ERLOTINIB S-1 THERAPY IN PATIENTS WITH PREVIOUSLY TREATED NON-SMALL-CELL LUNG CANCER: THORACIC ONCOLOGY RESEARCH GROUP (TORG) 0808/0913
    Sato, A.
    Nogami, N.
    Shinkai, T.
    Kozuki, T.
    Ogino, A.
    Misumi, Y.
    Hosomi, Y.
    Shimokawa, T.
    Hida, N.
    Seki, N.
    Honma, C.
    Okamoto, H.
    Shibuya, M.
    Morita, S.
    Watanabe, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 134 - 134
  • [34] Effect of EGFR amplification on survival of patients with EGFR mutation-positive non-small cell lung cancer.
    Xu, Yiquan
    Wang, Haibo
    Zheng, Xinlong
    Lin, Gen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial
    de Marinis, Filippo
    Vergnenegre, Alain
    Passaro, Antonio
    Dubos-Arvis, Catherine
    Carcereny, Enric
    Drozdowskyj, Ana
    Zeaiter, Ali
    Perez-Moreno, Pablo
    Rosell, Rafael
    FUTURE ONCOLOGY, 2015, 11 (03) : 421 - 429
  • [36] ADVERSE EVENTS COSTS ASSOCIATED WITH ERLOTINIB OR AFATINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR MUTATION-POSITIVE TUMOURS
    Isla, D.
    De Castro, J.
    Juan Vidal, O.
    Grau, S.
    Orofino, J.
    Gordo, R.
    Rubio-Terres, C.
    Rubio-Rodriguez, D.
    VALUE IN HEALTH, 2015, 18 (07) : A429 - A429
  • [37] Phase I/II study of S-1 combined with gemcitabine in elderly patients with advanced non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0502
    Seto, T.
    Yamanaka, T.
    Okamoto, H.
    Ogura, T.
    Shibuya, M.
    Takiguchi, Y.
    Masuda, N.
    Shinkai, T.
    Ichinose, Y.
    Watanabe, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies
    Atagi, Shinji
    Goto, Koichi
    Seto, Takashi
    Yamamoto, Nobuyuki
    Tamura, Tomohide
    Tajima, Kosei
    Inagaki, Naohito
    FUTURE ONCOLOGY, 2016, 12 (18) : 2117 - 2126
  • [39] Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer
    Sakata, Yoshihiko
    Kawamura, Kodai
    Shingu, Naoki
    Ichikado, Kazuya
    LUNG CANCER, 2016, 99 : 120 - 122
  • [40] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
12345